Related Experiment Video
Updated: Aug 5, 2026
06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Navigating the Debate on Menopausal Hormonal Therapy and Practical Prescribing
Genevieve Hofmann1, Nanette Santoro1
1University of Colorado Anschutz School of Medicine, Aurora, CO, USA.
Obstetrics and Gynecology Clinics of North America
|July 27, 2026
Summary
Menopause hormone therapy (MHT) can safely manage symptoms impacting quality of life and long-term health. Prescribing MHT effectively requires understanding proper timing, route, and dosage for optimal patient outcomes.
Area of Science:
- Reproductive Endocrinology
- Women's Health
- Clinical Pharmacology
Background:
- Menopause transition presents significant symptoms affecting quality of life and long-term health.
- Symptom management is often delayed due to insufficient clinician knowledge regarding menopause hormone therapy (MHT) safety and prescribing.
- Established expert consensus supports MHT as safe and effective for the majority of individuals.
Purpose of the Study:
- To address the gap in clinician knowledge regarding the safety and effective prescribing of MHT.
- To highlight the importance of individualized MHT regimens for optimal patient care.
- To provide guidance on the practical considerations for safe MHT initiation and management.
Main Methods:
- Review of current clinical guidelines and expert consensus statements on MHT.
- Analysis of evidence supporting the safety and efficacy of MHT for various menopausal symptoms.
- Discussion of key prescribing principles including timing, route, and dosage.
Main Results:
- MHT is considered safe and effective for most individuals experiencing menopausal symptoms.
- Specific factors such as timing of initiation, route of administration, and dosage are critical for safe and effective MHT.
- Addressing clinician knowledge gaps can improve MHT utilization and patient outcomes.
Conclusions:
- MHT is a valuable therapeutic option for managing menopausal symptoms and improving long-term health.
- Safe and effective MHT prescribing hinges on a thorough understanding of individualized patient needs and therapeutic options.
- Further education and resources are needed to enhance clinician confidence and competence in prescribing MHT.
Related Concept Videos
01:28Menopause
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
01:40Hormonal Regulation
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
01:33Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
01:22Hormonal Regulation of the Menstrual Cycle
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...